

REMARKS

This paper is responsive to an Office Action dated March 25, 2005. Prior to this response claims 1, 4-13, and 16-23 were pending. After amending claims 1 and 13, and canceling claims 10 and 22, claims 1, 4-9, 11-13, 16-21, and 23 remain pending.

Section 1 of the Office Action states that claims 4-8, 11-12, and 16-20 have been allowed.

Section 2 of the Office Action states that claims 10, 22, and 23 would be found allowable if rewritten in independent form including all the subject matter of the base and intervening claims.


In response, claim 1 has been amended to include the subject matter of claim 10. All claims dependent from claim 1 should now be found allowable. Claim 13 has been amended to include the subject matter of claim 22. All claims dependent from claim 13 should now be allowable.

Claim 23 should be allowable because it depends from allowed claim 16.

Section 3 of the Office Action states that claims 1, 9, 13, and 21 have been rejected as unpatentable under 35 U.S.C. 103(a) with respect to Kim et al. (6,621,114), in view of Currie et al. (2003/0234439) and Sohn et al. (6,753,230), and further in view of Hoffman (2004/0155846). This rejection should now be moot in light of the above-mentioned claim amendments.

It is believed that the application is in condition for allowance and reconsideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David Ripma', is written over a horizontal line. The signature is stylized with large loops and a long horizontal stroke at the end.

Date: April 13, 2005

Customer Number: 27,518
David C. Ripma, Patent Counsel
Sharp Laboratories of America, Inc.
5750 NW Pacific Rim Blvd.
Camas, WA 98607
Telephone: (360) 834-8754
Facsimile: (360) 817-8505
dripma@sharplabs.com